Empagliflozin with Metformin

Empagliflozin with Metformin is a combination medication used to treat type 2 diabetes. It combines two distinct classes of antidiabetic agents: empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and metformin, a biguanide.

Indications

This medication is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate.

Dosage

The dosage of Empagliflozin with Metformin will vary based on the individual's medical condition, response to treatment, and other medications they may be taking. It is essential to follow the prescribing healthcare professional's instructions.

Contra-Indications

-Hypersensitivity to empagliflozin or metformin -Severe renal impairment -Metabolic acidosis, including diabetic ketoacidosis

Special Precautions

Renal function should be assessed before starting and periodically during treatment. -Discontinue treatment if acute kidney injury occurs. -Monitor for signs and symptoms of ketoacidosis. -Discontinue before iodinated contrast imaging procedures. -Educate patients about the risks of genital mycotic infections and urinary tract infections.

Side Effects

Common side effects may include genital mycotic infections, urinary tract infections, hypoglycemia when combined with insulin or insulin secretagogues, increased urination, thirst, nausea, vomiting, diarrhea, and others. This is not an exhaustive list, and patients should report any unusual or severe side effects to their healthcare provider.

Drug Interactions

-Increased risk of hypoglycemia when used with insulin or insulin secretagogues. -Medications that may affect renal function or compete for elimination may interact with empagliflozin or metformin.